Avanos Medical, Inc.
NYSE•AVNS
CEO: Mr. Michael C. Greiner CPA
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2014-10-21
Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Contact Information
Market Cap
$647.39M
P/E (TTM)
-9.5
31.4
Dividend Yield
--
52W High
$15.68
52W Low
$9.30
52W Range
Rank60Top 89.2%
2.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$180.90M+0.00%
4-Quarter Trend
EPS
$0.08+0.00%
4-Quarter Trend
FCF
$21.30M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Total Net Sales Growth Total Net Sales reached $701.2M, reflecting 1.9% growth compared to $687.8M in 2024, driven by segment performance.
Specialty Nutrition Sales Surge Specialty Nutrition Systems sales grew 9.2% to $432.9M, driven by strong demand for both enteral feeding and neonate solutions.
Operating Loss Significantly Reduced GAAP Operating Loss narrowed to $(61.6)M from $(396.2)M, largely due to a substantial reduction in goodwill impairment charges.
Nexus Acquisition Completed Completed Nexus Acquisition in September 2025 for $27.0M, enhancing the strategic Specialty Nutrition Systems portfolio offerings.
Risk Factors
Competition and Obsolescence Risk Intense competition and rapid technological advances risk making current products obsolete or less competitive quickly across markets.
Global Trade and Tariffs Impact Reliance on Mexico manufacturing subjects operations to tariffs; new trade restrictions increase product costs and disrupt supply chains.
Reimbursement Coverage Uncertainty Uncertainty regarding Medicare coverage for RFA treatments, with a final determination expected early 2026, could reduce sales.
AI Integration Challenges Ineffective integration of new AI technology risks operational inefficiencies, reputational damage, and increased investment costs.
Outlook
Transformation Process Continues Restructuring initiatives, including organizational alignment, are expected to continue through 2026 for ongoing profitability enhancement.
Restructuring Savings Expected Anticipated annualized cost savings from restructuring initiatives range from $15.0M to $20.0M upon full implementation.
Focus on Core Segments Strategy remains focused on advancing core SNS and PM&R segments following recent divestiture and asset sales activities.
Capital Needs Anticipated Company may seek additional debt or equity financing to fund ongoing research, development activities, and future acquisitions.
Peer Comparison
Revenue (TTM)
$12.49B
$854.40M
$822.31M
Gross Margin (Latest Quarter)
97.7%
83.5%
73.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| BFLY | $1.05B | -13.6 | -35.3% | 6.9% |
| AVNS | $647.39M | -9.5 | -8.6% | 12.0% |
| BVS | $615.74M | 26.8 | 13.8% | 45.5% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.6%
Moderate Growth
4Q Net Income CAGR
-17.5%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 4, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data